AFUD announces award winners

The American Foundation for Urologic Disease has announced its 2004 PresidentialFounders Award winners. Those presented with the award were C. Eugene CarltonJr, MD; Jay W. Gillenwater, MD; Frank Hinman Jr, MD; Russell Scott Jr, MD;and E. Darracott Vaughan Jr, MD. Award winners are recognized for theirlong-term contributions to AFUD's mission.

Related Videos

Related Content

Advertisement

March 12th 2025

Novel drug delivery approach shows promise for UTI

Hannah Clarke

The method involves local delivery of the antibiotic gentamicin directly into the bladder tissue.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 10th 2025

Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC

Hannah Clarke

"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.

March 7th 2025

Data refute concerns about telehealth as Congress weighs legislation

Hannah Clarke

“Five years after telehealth suddenly became a routine part of care for most Americans, we show that it has not led to runaway utilization or spending. This kind of in-depth analysis can inform its future," says Chad Ellimoottil, MD, MS.

Related Content

Advertisement

March 12th 2025

Novel drug delivery approach shows promise for UTI

Hannah Clarke

The method involves local delivery of the antibiotic gentamicin directly into the bladder tissue.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 10th 2025

Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC

Hannah Clarke

"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.

March 7th 2025

Data refute concerns about telehealth as Congress weighs legislation

Hannah Clarke

“Five years after telehealth suddenly became a routine part of care for most Americans, we show that it has not led to runaway utilization or spending. This kind of in-depth analysis can inform its future," says Chad Ellimoottil, MD, MS.